Aditxt Inc. (ADTX) stock prices were up by 1.69% as of the market closing on October 12th, 2021. This brought the price per share up to USD$1.81 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 2.21%, bringing it up to USD$1.85.
ADTX Stock’s Presentations
October 7th, 2021 saw ADTX stock announce its upcoming presentation at the LD Micro Main Event. The biotech innovation company’s Co-Founder, Chairman, and CEO will present on October 13th, 2021. The event will also include 1 on 1 meetings with investors and analysts. The event will take place at the Luxe Sunset Hotel in California and will also be accessible virtually. The company has launched its AditxtScore for Covid-19 in several states, with intentions to roll out across the nation. AditxtScore is a comprehensive immune monitoring solution that is being used in the pandemic to facilitate a return to normalcy with information, data, and confidence.
Acquisition of AiPharma
ADTX stock announced having entered into a binding agreement on October 5th, 2021. As per the agreement, the company will purchase all of the assets of AiPharma through the sale of one of its wholly owned group subsidiaries. The company is a biotech innovation with a mission to improve the health of the immune system. It focuses on the discovery, development, and commercialization of antiviral therapies across a broad spectrum of infection diseases. AiPharma is a complementary biopharmaceutical company that holds exclusive rights to Avigan/Reeqonus/Qifenda and all formulations of favipiravir, which is a broad spectrum oral antiviral drug that targets infectious diseases like Covid-19. These exclusive rights are either held directly or through the company’s worldwide affiliates.
Scope of Collaboration
Avigan has been granted full marketing authorization or EUA in various markets for the treatment of Covid-19. These markets include Mexico, India, Indonesia, Thailand, and Malaysia, and other countries. UK, UAE, Greek, Hungarian, and Saudi Arabian markets are purchasing the Avigan treatment under compassionate use programs. AiPharma generates revenues from the global sales of Avigan/Reeqonus through its 50% equity stake in the Global Response Aid (GRA). Global sales of Avigan have surpassed USD$150 million in 2021, with at least 1.5 million Covid-19 patients being treated with Avigan to date.
Future Outlook for ADTX Stock
The company has reported a promising quarter, consolidated by the expanded scope of opportunities afforded to it. These opportunities are a result of ADTX stock’s upcoming presentations and their collaboration with AiPharma. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.